知镜 Cognispect · 医学文献与研究工作台

The conversion of pulmonary artery smooth muscle cells to eosinophil-like cells exacerbates the progression of pulmonary arterial hypertension with increased secretion of 12-HETE.

Jiao Z, Xu G, Zhu F, Zhang Y, Xu J, Chen Z, Yan A, Piao M, Dong Z, Chen L, Jia T, Zhang Y, Wang C, Chen Y, Xu J, He Q, Zhang J.
Biochemical pharmacology · 2026-11-14 · PMID 43033933

文献摘要

Pulmonary arterial hypertension (PAH) is characterised by progressive pulmonary arterial (PA) vascular remodeling, with abnormal phenotypic transformation of pulmonary artery smooth muscle cells (PASMCs) playing a central role. Arachidonic acid (AA) metabolites have been implicated in this process, yet the underlying cellular and molecular mechanisms by which its metabolite 12-hydroxyeicosatetraenoic acid (12-HETE) contributes to PAH remain incompletely understood. Plasma concentrations of 12-HETE were significantly elevated in PAH patients. In SU5416/hypoxia (SuHx)-induced PAH mouse model, the 12/15-lipoxygenase (12/15-LOX) inhibitor ML-351 markedly attenuated disease progression. Single-cell RNA sequencing (scRNA-seq) analysis revealed a unrecognized phenotypic transdifferentiation of a subset of PASMCs into eosinophil-like (Eos-like) cells. Mechanistically, studies utilizing EOS-deficient (ΔdblGATA) mice demonstrated that these newly Eos-like cells, along with native eosinophils (EOS), secrete 12-HETE. In vitro CCK-8 assays confirmed that hypoxia-induced PASMC proliferation was attenuated by the leukotriene B4 receptor 2 (BLT2) antagonist LY255283, confirming that the 12-HETE/BLT2 axis drives PASMC proliferation, thereby creating a positive feedback loop that amplifies vascular remodeling. These findings establish the 12-HETE as a critical mediator of a novel EOS-PASMC signaling axis that drives PA vascular remodeling in PAH. This study highlights a promising new therapeutic strategy for PAH.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。